Triavera Capital LLC Decreases Stock Position in Danaher Corporation $DHR

Key Points

• Triavera Capital LLC reduced its stake in Danaher Corporation by 35.3% during the first quarter, holding 23,421 shares valued at approximately $4.8 million.
• Analysts have mixed opinions on Danaher, with 17 rating it as a 'Buy' and three as a 'Hold', while the consensus target price is set at $246.35.
• Danaher reported an EPS of $1.80 for the last quarter, surpassing expectations and reflecting a revenue growth of 3.4% year-over-year.

Triavera Capital LLC cut its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 35.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 23,421 shares of the conglomerate's stock after selling 12,794 shares during the period. Danaher comprises approximately 2.8% of Triavera Capital LLC's holdings, making the stock its 17th largest position. Triavera Capital LLC's holdings in Danaher were worth $4,801,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. MGO One Seven LLC raised its stake in Danaher by 485.7% during the 1st quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate's stock valued at $5,145,000 after buying an additional 20,813 shares during the last quarter. Asahi Life Asset Management CO. LTD. purchased a new stake in Danaher during the 1st quarter valued at $539,000. Horizon Financial Services LLC raised its stake in Danaher by 20,400.0% during the 1st quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock valued at $1,681,000 after buying an additional 8,160 shares during the last quarter. Texas Capital Bank Wealth Management Services Inc raised its stake in Danaher by 6.1% during the 1st quarter. Texas Capital Bank Wealth Management Services Inc now owns 34,763 shares of the conglomerate's stock valued at $7,126,000 after buying an additional 2,009 shares during the last quarter. Finally, EFG Asset Management Americas Corp. grew its position in shares of Danaher by 13.1% during the 1st quarter. EFG Asset Management Americas Corp. now owns 36,080 shares of the conglomerate's stock valued at $7,396,000 after acquiring an additional 4,191 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

DHR has been the subject of a number of recent research reports. Guggenheim reissued a "buy" rating and set a $250.00 price objective on shares of Danaher in a research report on Wednesday, July 23rd. Robert W. Baird boosted their price objective on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research report on Friday, July 18th. Scotiabank raised shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective for the company in a research report on Friday, July 11th. Evercore ISI cut their price objective on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Finally, UBS Group cut their price objective on shares of Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a research report on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $246.35.

Insider Buying and Selling

In other Danaher news, Director Teri List sold 2,778 shares of the business's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director owned 20,751 shares in the company, valued at $4,379,706.06. The trade was a 11.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 11.20% of the stock is currently owned by insiders.

Danaher Price Performance

Danaher stock traded down $4.39 during mid-day trading on Tuesday, hitting $194.24. The stock had a trading volume of 3,344,891 shares, compared to its average volume of 2,899,976. The firm has a market capitalization of $139.09 billion, a P/E ratio of 41.33, a P/E/G ratio of 2.77 and a beta of 0.75. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The firm's 50 day moving average is $201.82 and its 200 day moving average is $199.20. Danaher Corporation has a one year low of $171.00 and a one year high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. Danaher's quarterly revenue was up 3.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, sell-side analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.7%. Danaher's payout ratio is currently 27.23%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.